Sept. 10, 2023

Ravi Samavedam - Chief Innovation Officer of Azzur Group

In this episode of Life Science Success, my guest is Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience in the biotech and pharma industries, Ravi is a seasoned Biochemical Engineer who has worn many hats...

In this episode of Life Science Success, my guest is Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience in the biotech and pharma industries, Ravi is a seasoned Biochemical Engineer who has worn many hats throughout his career. Prior to his current role, he served as the President of Azzur Cleanrooms on Demand™ and was also the General Manager of Azzur Boston. He's an expert in areas such as phase-appropriate cGMP implementation, process validation, and supplier management.

 

  • Ravi Samavedam is the Chief Innovation Officer at Azzur Group, with over two decades of experience in the biotech and pharma industries. He transitioned from a biochemical engineer to his current role, having worked at companies like Baxter, Shire, and Amgen.

  • His role at Azzur Group involves exploring potential growth areas for the company, such as their "Clean Rooms on Demand" business. This service aims to provide a flexible, cost-effective solution for companies in the biopharma sector, bridging the gap between traditional manufacturing options.

  • Samavedam emphasizes the importance of innovation and impact in the healthcare industry. He believes that smaller, agile companies like Azzur can make a more significant impact compared to larger organizations where individual contributions may get diluted.

  • One of the challenges he faces is educating the industry about new, more efficient models of operation. Traditional methods are often deeply ingrained, making it difficult for companies to see the value in innovative solutions like Azzur's.

  • His leadership philosophy is "Don't let perfect get in the way of good," emphasizing the importance of practicality and risk mitigation in the pursuit of excellence. He is excited about the future of personalized medicine and believes that technology will continue to reduce inherent risks in biopharma processes.

 

Please check out our Life Science Success Resources.  You will find tools that will support growing companies and books for authors I have interviewed.